PTPA and endometrial carcinoma: However, the biochemical antagonists of protein kinases, the protein phosphatases, have more recently also come into the limelight as potential targets in cancer, particularly in type II endometrial carcinomas, where the tumour suppressive phosphatase protein phosphatase type 2A (PP2A) is frequently mutated.